Concord Biotech Share Price

    NSE
    0.00
    0.00 (0.00%)
    CONCORDBIO
    BUY
    The current prices are delayed, login or Open Demat Account for live prices.

    Concord Biotech Stock Performance

    1W Return5.02
    1Y Return11.66
    Today's Low1885.1
    Prev. Close1,920.50
    Mkt Cap (Cr.)19,813.26
    1M Return-5.72
    3Y Return0.00
    52-Week High2664
    Open1,925.00
    PE Ratio53.12
    6M Return-13.04
    Today's High1939
    52-Week Low1345
    Face Value1

    Concord Biotech Company background

    Founded in: 1984
    Managing director: SUDHIR JAIRAM VAID
    Concord Biotech Limited was originally incorporated as Servomed Pharmaceuticals Private Limited at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies. Thereafter, name of the Company was changed to Concord Biotech Limited dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC.The Company is an Indiabased bio pharma and one of the leading global developers and manufacturers of select fermentationbased APIs across immunosuppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India. Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. Its API manufacturing facilities are located at Dholka and Limbasi, and formulations facility at Valthera in Gujarat.In 2000, the Company was acquired by the Promoter, Mr. Sudhir Vaid. In 2016, the Company launched formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded to the United States. It established a facility at Valthera, Gujarat.It set up a joint venture in Japan to grow business in 2018.In 2019, the Company received two ANDA approvals. It expanded their business into critical care segment in India. It commenced marketing of Mycophenolate Mofetil Capsules USP 250 mg. In 2020, Mycophenolate Sodium Tablets got launched in the US market.The Company added a new manufacturing unit at Limbasi, which commenced operations in July, 2021. As of March 31, 2022, the Company had 6 fermentationbased immunosuppressant APIs, including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus and pimecrolimus. It had 3 manufacturing facilities in the state of Gujarat, India, comprising API manufacturing facilities in Dholka and Limbasi and a formulation manufacturing facility in Valthera, which were commercialized in 2000, 2021 and 2016, respectively. Their total annual installed fermentation capacity for APIs was 1,250 m3, as of March 31, 2022. It had a total of 41 manufacturing blocks and 387 reactors in the Dholka and Limbasi facilities. In August 2023, Company made an Initial Public Offer by issuing 20,925,652 Equity Shares aggregating to Rs 1551 Crores through Offer for Sale.The Company has launched 21 new formulations products in 2024.

    As of , Concord Biotech share price is ₹1893.9. The stock opened at ₹1925 and had closed at ₹1920.5 the previous day. During today’s trading session, Concord Biotech share price moved between ₹1,885.10 and ₹1,939.00, with an average price for the day of ₹1912.05. Over the last 52 weeks, the stock has recorded a low of ₹1,345.00 and a high of ₹2,664.00. In terms of performance, Concord Biotech share price has declined by 13% over the past six months and has increased by 13.22% over the last year.

    Read More
    View details of Market Depth

    Concord Biotech Fundamental

    Market Cap (in crs)

    19,813.26

    Face Value

    1

    Turnover (in lacs)

    2,696.00

    Key Metrics

    Qtr Change %
    28.91% Fall from 52W High
    10
    Dividend yield 1yr %
    0

    Concord Biotech Key Financials

    View more
    Loading chart...
    Loading chart...
    Loading chart...
    Loading chart...
    Concord Biotech Quarterly Revenue
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    429.88 Cr
    244.22 Cr
    310.18 Cr
    215.8 Cr
    318.97 Cr
    Concord Biotech Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022
    1244.53 Cr
    1050.72 Cr
    888.48 Cr
    736.35 Cr
    Concord Biotech Quarterly Net Profit/Loss
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    141.94 Cr
    74.09 Cr
    98.7 Cr
    58.24 Cr
    97.21 Cr
    Concord Biotech Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022
    372.96 Cr
    304.73 Cr
    238.13 Cr
    178.57 Cr

    Concord Biotech Result Highlights

    • Concord Biotech Ltd reported a 27.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 15.8%.

    • Its expenses for the quarter were up by 24.6% QoQ and 25.0% YoY.

    • The net profit increased 25.2% QoQ and increased 3.9% YoY.

    • The earnings per share (EPS) of Concord Biotech Ltd stood at 9.1 during Q4FY25.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Top Mutual Fund Invested in Concord Biotech

    Promoter
    44.1%
    Foreign Institutions
    9.1%
    Mutual Funds
    4.7%
    Domestic Institutions
    8.9%
    Public
    37.9%
    Promoter
    44.1%
    Foreign Institutions
    9.4%
    Mutual Funds
    5.2%
    Domestic Institutions
    9.1%
    Public
    37.4%
    Promoter
    44.1%
    Foreign Institutions
    8.3%
    Mutual Funds
    4.9%
    Domestic Institutions
    9.7%
    Public
    37.9%
    Promoter
    44.1%
    Foreign Institutions
    8.1%
    Mutual Funds
    5%
    Domestic Institutions
    9.9%
    Public
    38%
    Promoter
    44.1%
    Foreign Institutions
    7.1%
    Mutual Funds
    5.3%
    Domestic Institutions
    10.4%
    Public
    38.4%
    Promoter
    44.1%
    Foreign Institutions
    6.5%
    Mutual Funds
    5.2%
    Domestic Institutions
    8.5%
    Public
    41%

    Concord Biotech Technical Analysis

    Moving Averages Analysis
    0.00
    Current Price
    Bullish Moving Averages
    16
    Bearish Moving Averages
    0
    5Day EMA
    1,869.50
    10Day EMA
    1,846.90
    12Day EMA
    1,843.30
    20Day EMA
    1,837.00
    26Day EMA
    1,831.20
    50Day EMA
    1,802.90
    100Day EMA
    1,794.00
    200Day EMA
    1,786.70
    5Day SMA
    1,865.00
    10Day SMA
    1,831.00
    20Day SMA
    1,811.50
    30Day SMA
    1,887.80
    50Day SMA
    1,784.50
    100Day SMA
    1,707.20
    150Day SMA
    1,848.10
    200Day SMA
    1,874.90
    Delivery & Volume
    Loading chart...

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    67232 Rs
    151594 Rs
    Week Rs
    134428 Rs
    268659 Rs
    Month Rs
    144982 Rs
    247605 Rs
    1,906.00
    Pivot
    Resistance
    First Resistance
    1,926.90
    Second Resistance
    1,959.90
    Third Resistance
    1,980.80
    Support
    First Support
    1,873
    Second support
    1,852.10
    Third Support
    1,819.10
    Relative Strength Index
    58.03
    Money Flow Index
    70.19
    MACD
    12.08
    MACD Signal
    3.92
    Average True Range
    68.96
    Average Directional Index
    18.47
    Rate of Change (21)
    -4.02
    Rate of Change (125)
    -15.48
    Name
    Holding Percent
    Government Pension Fund Global
    2.66
    Tata Aia Life Insurance Co Ltd Unit Linked Multi Cap Fund
    1.55
    Axis Max Life Insurance Limited A/C Reversionary Bonus Participating - Equity
    1.52

    Concord Biotech Latest News

    18 JUL 2025 | Friday

    Concord Biotech Ltd - 543960 - Successful Completion Of EU GMP Inspection

    08 JUL 2025 | Tuesday

    Concord Biotech Ltd - 543960 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    02 JUL 2025 | Wednesday

    Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Acquisition

    View More

    Concord Biotech Share Price FAQs

    Concord Biotech share price in the past 1-year return was 11.65. The Concord Biotech share hit a 1-year low of Rs. 1345 and a 1-year high of Rs. 2664.

    The market cap of Concord Biotech is Rs. 19813.26 Cr. as of 18/7/2025.

    The PE ratios of Concord Biotech is 53.12 as of 18/7/2025.

    The PB ratios of Concord Biotech is 10.92 as of 18/7/2025

    The Mutual Fund Shareholding in Concord Biotech was 4.68% at the end of 18/7/2025.

    You can easily buy Concord Biotech shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Concord Biotech share price is ₹2664 and ₹1345 as of 18/7/2025.

    Please be aware that Concord Biotech stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    65.06
    -1.20 (-1.81%)
    133.84
    -1.07 (-0.79%)
    680.25
    -1.45 (-0.21%)
    2,596.10
    -20.50 (-0.78%)
    157.39
    -1.85 (-1.16%)
    376.00
    -5.45 (-1.43%)
    162.37
    +2.47 (+1.54%)
    257.20
    -2.45 (-0.94%)
    394.75
    -9.45 (-2.34%)
    407.90
    -5.55 (-1.34%)
    Top Gainers
    266.95
    +6.35 (+2.44%)
    942.00
    +18.70 (+2.03%)
    162.37
    +2.47 (+1.54%)
    246.31
    +2.44 (+1.00%)
    2,472.20
    +23.10 (+0.94%)
    Top Losers
    1,099.30
    -60.50 (-5.22%)
    645.50
    -19.95 (-3.00%)
    394.75
    -9.45 (-2.34%)
    739.50
    -12.30 (-1.64%)
    1,901.00
    -28.90 (-1.50%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -